The same authors also published a separate report indicated that in a patient with gastroesophageal junction adenocarcinoma MDM2 and EGFR amplifications was found, 3.5% out of 100,000 samples had MDM2 amplification (10). This evidence concerns the gene MDM2 and gastroesophageal junction adenocarcinoma.